Study S000383

A Double-Blind, Multicenter, Randomized Study Evaluating the Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Relationship in T2DMs Treated With 14 Weeks Injection of Polyethylene Glycol Loxenatide

ClinicalTrials.gov record

Registration

Registration: NCT01965496
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 64
Start: 2012-03
Primary completion: 2013-03
Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.
Conditions: Type 2 Diabetes
Interventions: DRUG:PEX168
Results posted: FALSE

Registered primary outcomes

To assess HbA1C levels after 14 weeks continuous treatment [14 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.